Fate Therapeutics, Inc. (FATE)
2.435
+0.10
(+4.51%)
USD |
NASDAQ |
Aug 24, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics EPS Diluted (Quarterly) : -0.2505 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2505 |
| March 31, 2026 | -0.26 |
| December 31, 2025 | -0.2715 |
| September 30, 2025 | -0.271 |
| June 30, 2025 | -0.2874 |
| March 31, 2025 | -0.3178 |
| December 31, 2024 | -0.4428 |
| September 30, 2024 | -0.4048 |
| June 30, 2024 | -0.3271 |
| March 31, 2024 | -0.4748 |
| December 31, 2023 | -0.4474 |
| September 30, 2023 | -0.4583 |
| June 30, 2023 | -0.5361 |
| March 31, 2023 | -0.1926 |
| December 31, 2022 | -0.5797 |
| September 30, 2022 | -0.8613 |
| June 30, 2022 | -0.787 |
| March 31, 2022 | -0.6818 |
| December 31, 2021 | -0.7164 |
| September 30, 2021 | -0.4539 |
| June 30, 2021 | -0.5845 |
| March 31, 2021 | -0.4826 |
| December 31, 2020 | -0.608 |
| September 30, 2020 | -0.6754 |
| June 30, 2020 | -0.354 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4417 |
| December 31, 2019 | -0.3744 |
| September 30, 2019 | -0.3976 |
| June 30, 2019 | -0.36 |
| March 31, 2019 | -0.3044 |
| December 31, 2018 | -0.2481 |
| September 30, 2018 | -0.3097 |
| June 30, 2018 | -0.37 |
| March 31, 2018 | -0.27 |
| December 31, 2017 | -0.29 |
| September 30, 2017 | -0.26 |
| June 30, 2017 | -0.23 |
| March 31, 2017 | -0.24 |
| December 31, 2016 | -0.21 |
| September 30, 2016 | -0.27 |
| June 30, 2016 | -0.29 |
| March 31, 2016 | -0.29 |
| December 31, 2015 | -0.26 |
| September 30, 2015 | -0.24 |
| June 30, 2015 | -0.33 |
| March 31, 2015 | -0.38 |
| December 31, 2014 | -0.30 |
| September 30, 2014 | -0.32 |
| June 30, 2014 | -0.30 |
| March 31, 2014 | -0.34 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -30.16M |
| Revenue (Quarterly) | 2.082M |
| Total Expenses (Quarterly) | 32.24M |
| Enterprise Value | 193.81M |
| Gross Profit Margin (Quarterly) | -33.53% |
| Profit Margin (Quarterly) | -1.45K% |
| Earnings Yield | -43.24% |
| Normalized Earnings Yield | -43.10 |